Last reviewed · How we verify
cyclophosphamide,cyclosporine A
cyclophosphamide,cyclosporine A is a Small molecule drug developed by Xiaofan Zhu. It is currently FDA-approved. Also known as: Drug,Mesnaum.
Cyclophosphamide and cyclosporine A, marketed by Xiaofan Zhu, are established drugs with a key composition patent expiring in 2028. The primary strength lies in their well-established market presence and long-term use in various indications. The primary risk is the potential increase in generic competition following the 2028 patent expiry.
At a glance
| Generic name | cyclophosphamide,cyclosporine A |
|---|---|
| Also known as | Drug,Mesnaum |
| Sponsor | Xiaofan Zhu |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (PHASE2)
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NA)
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (PHASE1)
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (PHASE2)
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (PHASE3)
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclophosphamide,cyclosporine A CI brief — competitive landscape report
- cyclophosphamide,cyclosporine A updates RSS · CI watch RSS
- Xiaofan Zhu portfolio CI
Frequently asked questions about cyclophosphamide,cyclosporine A
What is cyclophosphamide,cyclosporine A?
Who makes cyclophosphamide,cyclosporine A?
Is cyclophosphamide,cyclosporine A also known as anything else?
What development phase is cyclophosphamide,cyclosporine A in?
Related
- Manufacturer: Xiaofan Zhu — full pipeline
- Also known as: Drug,Mesnaum